f1
Correspondence: Dr Michel Bertrand, Department of Cardiology, Hopital Cardiologique, Boulevard du Pr Leclercq, 59037 Lille, France.

References

1
Davies
MJ
, Richardson PJ, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.
Br Heart J
 .
1993
;
69
:
377
–381
2
Davies
M
. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention.
Eur Heart J
 .
1995
;
16
:
3
–7
3
Davies
M
. The composition of coronary artery plaque.
N Engl J Med
 .
1997
;
336
:
1312
–1313
4
Task force on the management of acute myocardial infarction of the European Society of Cardiology, Acute myocardial infarction: prehospital and in-hospital management, Eur Heart J
5
J Am Coll Cardiol
 .
2000
;
36
:
959
–969
6
Braunwald
E
, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
J Am Coll Cardiol
 .
2000
;
36
:
970
–1062
7
Braunwald
E
, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina).
Circulation
 .
2000
;
102
:
1193
–1209
8
Hall
R
. Guidelines on the management of unstable angina.
Heart
 .
2001
;
85
:
132
9
Verstraete
M
, Prentice CR, Samama M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy.
Chest
 .
2000
;
117
:
1755
–1770
10
Schwartz
PJ
, Breithardt G, Howard AJ, Julian DG, Rehnqvist Ahlberg N. Task Force Report: The legal implications of medical guidelines. A Task Force of the European Society of Cardiology.
Eur Heart J
 .
1999
;
20
:
1152
–1157
11
Battler
A
. European Heart Survey of Acute Coronary syndromes.
Eur Heart J
 .
2002
;
23
:
1190
–1201
12
Fox
K
, Goodman S, Klein W, Brieger D, Steg P, Dabbous O, Avezum A. Managements of acute coronary syndromes. Variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE).
Eur Heart J
 .
2002
;
23
:
1177
–1189
13
Am Heart J
 .
2001
;
141
:
190
–199
14
Eagle
KA
, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).
Lancet
 .
2002
;
359
:
373
–377
15
Fuster
VBL
, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes.
N Engl J Med
 .
1992
;
326
:
242
–250
16
Fuster
V
. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
Circulation
 .
1994
;
90
:
2126
–2146
17
Virmani
R
, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.
Arterioscler Thromb Vasc Biol
 .
2000
;
20
:
1262
–1275
18
Libby
P
. Current concepts of the pathogenesis of the acute coronary syndromes.
Circulation
 .
2001
;
104
:
365
–372
19
Burke
APFA
, Tang AL. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.
N Engl J Med
 .
1997
;
336
:
1276
–1282
20
Davies
MJ
. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.
Circulation
 .
1996
;
94
:
2013
–2020
21
Farb
ABA
, Tang AL. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death.
Circulation
 .
1996
;
93
:
1354
–1363
22
Arbustini
EDBB
, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction.
Heart
 .
1999
;
82
:
269
–272
23
Libby
P
. Molecular basis of the acute coronary syndromes.
Circulation
 .
1995
;
91
:
2844
–2850
24
Moreno
PR
, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.
Circulation
 .
1994
;
90
:
775
–778
25
Kaartinen
M
, van der Wal A, van der Loos C. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture.
J Am Coll Cardiol
 .
1998
;
32
:
606
–612
26
Arbustini
E
, De Servi S, Bramucci E. Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty.
Am J Cardiol
 .
1995
;
75
:
675
–682
27
Arbustini
E
, Morbini P, De Servi S. Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group.
G Ital Cardiol
 .
1996
;
26
:
623
–633
28
Toschi
VGR
, Lettino M, Fallon JT. Tissue factor predicts the thrombogenicity of human atherosclerotic components.
Circulation
 .
1997
;
95
:
594
–599
29
Willerson
JTGP
, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications.
Circulation
 .
1989
;
80
:
198
–205
30
Falk
E
. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes.
Am J Cardiol
 .
1989
;
63
:
114E
–120E
31
Falk
E
, Fuster V. Angina pectoris and disease progression.
Circulation
 .
1995
;
92
:
2033
–2035
32
Falk
E
, Shah P, Fuster V. Coronary plaque disruption.
Circulation
 .
1995
;
92
:
657
–671
33
van Domburg
RT
, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course.
J Am Coll Cardiol
 .
1998
;
31
:
1534
–1539
34
Lee
TH
, Cook EF, Weisberg M, Sargent RK, Wilson C, Goldman L. Acute chest pain in the emergency room. Identification and examination of low-risk patients.
Arch Intern Med
 .
1985
;
145
:
65
–69
35
Fesmire
FM
, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain.
Ann Emerg Med
 .
1998
;
31
:
3
–11
36
Fisch
C
. The clinical ECG; sensitivity and specificity. : Elsevier; 1997.
37
Savonitto
S
, Ardissino D, Granger CB. Prognostic value of the admission electrocardiogram in acute coronary syndromes.
JAMA
 .
1999
;
281
:
707
–713
38
Rouan
GW
, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman L. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study).
Am J Cardiol
 .
1989
;
64
:
1087
–1092
39
McCarthy
BD
, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature.
J Gen Intern Med
 .
1990
;
5
:
365
–373
40
Pozen
MW
, D'Agostino RB, Selker HP, Sytkowski PA, Hood WB Jr. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease. A prospective multicenter clinical trial.
N Engl J Med
 .
1984
;
310
:
1273
–1278
41
Davies
E
, Gawad Y, Takahashi M. Analytical performance and clinical utility of a sensitive immunoassay for determination of human cardiac troponin I.
Clin Biochem
 .
1997
;
30
:
479
–490
42
Katus
HA
, Looser S, Hallermayer K. Development and in vitro characterization of a new immunoassay of cardiac troponin T.
Clin Chem
 .
1992
;
38
:
386
–393
43
Jaffe
AS
, Ravkilde J, Roberts R. It's time for a change to a troponin standard.
Circulation
 .
2000
;
102
:
1216
–1220
44
Giannitsis
E
, Muller-Bardorff M, Kurowski V. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.
Circulation
 .
2000
;
102
:
211
–217
45
Missov
E
, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure.
Circulation
 .
1997
;
96
:
2953
–2958
46
Lauer
B
, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis.
J Am Coll Cardiol
 .
1997
;
30
:
1354
–1359
47
Smith
SC
, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates.
Circulation
 .
1997
;
95
:
163
–168
48
McLaurin
MD
, Apple FS, Voss EM, Herzog CA, Sharkey SW. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle.
Clin Chem
 .
1997
;
43
:
976
–982
49
Frankel
WL
, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure.
Am J Clin Pathol
 .
1996
;
106
:
118
–123
50
Labugger
R
, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction.
Circulation
 .
2000
;
102
:
1221
–1226
51
Cannon
CP
, Weintraub WS, Demopoulos LA. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
N Engl J Med
 .
2001
;
344
:
1879
–1887
52
Lancet
 .
1999
;
354
:
708
–715
53
Lindahl
B
, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy.
J Am Coll Cardiol
 .
2001
;
38
:
979
–986
54
Wu
AH
, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases.
Clin Chem
 .
1999
;
45
:
1104
–1121
55
Cohen
M
, Demers C, Gurfinkel EP. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
N Engl J Med
 .
1997
;
337
:
447
–452
56
Campbell
RWF
, Turpie AGG, Maseri A. Management strategies for a better outcome in unstable coronary artery disease.
Clin Cardiol
 .
1998
;
21
:
314
–322
57
Braunwald
E
, Jones RH, Mark DB. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research.
Circulation
 .
1994
;
90
:
613
–622
58
Theroux
P
, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction.
Circulation
 .
1998
;
97
:
1195
–1206
59
Braunwald
E
. Unstable angina. A classification.
Circulation
 .
1989
;
80
:
410
–414
60
van Miltenburg-van Zijl
AJ
, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris.
J Am Coll Cardiol
 .
1995
;
25
:
1286
–1292
61
Nyman
I
, Areskog M, Areskog NH, Swahn E, Wallentin L. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group.
J Intern Med
 .
1993
;
234
:
293
–301
62
Diderholm
E
, Andren B, Frostfeldt G. The Fast Revascularization during InStability in Coronary artery d. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease. The FRISC II ECG substudy.
Eur Heart J
 .
2002
;
23
:
41
–49
63
Circulation
 .
1994
;
89
:
1545
–1556
64
Andersen
K
, Eriksson P. Ischaemia detected by continuous on-line vectocardiographic monitoring predictes unfavourable outcome in patients admitted with probable unstable coronary artery disease.
Coron Artery Dis
 .
1996
;
7
:
753
–760
65
Gottlieb
SO
, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina.
N Engl J Med
 .
1986
;
314
:
1214
–1219
66
Langer
A
, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome.
J Am Coll Cardiol
 .
1989
;
13
:
1495
–1502
67
Larsson
H
, Areskog M, Areskog NH. The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Eur Heart J
 .
1995
;
16
:
888
–893
68
Wilcox
I
, Ben Freedman S, Kelly DT, Harris PJ. Clinical significance of silent ischemia in unstable angina pectoris.
Am J Cardiol
 .
1990
;
65
:
1313
–1316
69
Patel
DJ
, Holdright DR, Knight CJ. Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram.
Heart
 .
1996
;
75
:
222
–228
70
Akkerhuis
KM
, Klootwijk PA, Lindeboom W. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients.
Eur Heart J
 .
2001
;
22
:
1997
–2006
71
Olatidoye
AG
, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies.
Am J Cardiol
 .
1998
;
81
:
1405
–1410
72
Ottani
F
, Galvani M, Nicolini FA. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes.
Am Heart J
 .
2000
;
140
:
917
–927
73
Morrow
DA
, Cannon CP, Rifai N. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
JAMA
 .
2001
;
286
:
2405
–2412
74
Hamm
CW
, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus HA. The prognostic value of serum troponin T in unstable angina.
N Engl J Med
 .
1992
;
327
:
146
–150
75
Pettersson
T
, Ohlsson O, Tryding N. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death.
Eur Heart J
 .
1992
;
13
:
1387
–1392
76
Ravkilde
J
, Hansen AB, Horder M, Jorgensen PJ, Thygesen K. Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2·5-year follow-up study in 156 consecutive patients.
Cardiology
 .
1992
;
80
:
143
–151
77
Stubbs
P
, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina.
BMJ
 .
1996
;
313
:
262
–264
78
Wu
AH
, Abbas SA, Green S. Prognostic value of cardiac troponin T in unstable angina pectoris.
Am J Cardiol
 .
1995
;
76
:
970
–972
79
Lindahl
B
. Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis.
Ups J Med Sci
 .
1996
;
101
:
193
–232
80
Lindahl
B
, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group.
Circulation
 .
1996
;
93
:
1651
–1657
81
Lindahl
B
, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
J Am Coll Cardiol
 .
1997
;
29
:
43
–48
82
Antman
EM
, Tanasijevic MJ, Thompson B. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.
N Engl J Med
 .
1996
;
335
:
1342
–1349
83
Luscher
MS
, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Circulation
 .
1997
;
96
:
2578
–2585
84
Galvani
M
, Ottani F, Ferrini D. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina.
Circulation
 .
1997
;
95
:
2053
–2059
85
Lindahl
B
, Andren B, Ohlsson J, Venge P, Wallentin L. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group.
Eur Heart J
 .
1997
;
18
:
762
–770
86
Lindahl
B
, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
N Engl J Med
 .
2000
;
343
:
1139
–1147
87
Holmvang
LAK
, Andersen K, Dellborg M. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease.
Am J Cardiol
 .
1999
;
83
:
667
–674
88
Dellborg
M
, Andersen K. Key factors in the identification of the high-risk patient with unstable coronary artery disease: clinical findings, resting 12-lead electrocardiogram, and continuous electrocardiographic monitoring.
Am J Cardiol
 .
1997
;
80
:
35E
–39E
89
Hamm
CW
, Heeschen C, Goldmann B. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
N Engl J Med
 .
1999
;
340
:
1623
–1629
90
Heeschen
C
, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
Lancet
 .
1999
;
354
:
1757
–1762
91
Newby
LK
, Ohman EM, Christenson RH. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy.
Circulation
 .
2001
;
103
:
2891
–2896
92
Morrow
DA
, Antman EM, Tanasijevic M. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.
J Am Coll Cardiol
 .
2000
;
36
:
1812
–1817
93
Toss
H
, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
Circulation
 .
1997
;
96
:
4204
–4210
94
Becker
RCC
, Bovill E. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial).
Am J Cardiol
 .
1996
;
78
:
142
–147
95
Pollak
H
, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis?
Thromb Haemost
 .
1991
;
66
:
406
–409
96
Kuller
LH
, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial.
Am J Epidemiol
 .
1996
;
144
:
537
–547
97
de Lemos
JA
, Morrow DA, Bentley JH. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med
 .
2001
;
345
:
1014
–1021
98
Lindmark
E
, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.
JAMA
 .
2001
;
286
:
2107
–2113
99
O'Malley
T
, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes.
Eur Heart J
 .
2001
;
22
:
1226
–1234
100
Ardissino
D
, Merlini PA, Gamba G. Thrombin activity and early outcome in unstable angina pectoris.
Circulation
 .
1996
;
93
:
1634
–1639
101
Ernofsson
M
, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Thromb Haemost
 .
1998
;
79
:
491
–494
102
Meade
TW
. Routine measurement of fibrinogen concentration. Clinically feasible.
BMJ
 .
1993
;
307
:
1562
103
Meade
TW
, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischaemic heart disease in women.
BMJ
 .
1996
;
312
:
1581
104
Meade
TW
. Fibrinogen in ischaemic heart disease.
Eur Heart J
 .
1995
;
16
:
31
–34
105
Munkvad
S
, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction.
Eur Heart J
 .
1990
;
11
:
525
–528
106
Hamsten
A
, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
Lancet
 .
1987
;
2
:
3
–9
107
Kruskal
JCP
, Franks J, Kirsch R. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease.
N Eng J Med
 .
1987
;
22
:
1361
–1365
108
Wilcox
I
, Freedman SB, Allman KC. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris.
J Am Coll Cardiol
 .
1991
;
18
:
677
–683
109
Wilcox
I
, Ben Freedman SB, Li JN, Harris PJ, Kelly DT. Comparison of exercise stress testing with ambulatory electrocardiographic monitoring in the detection of myocardial ischemia after unstable angina pectoris.
Am J Cardiol
 .
1991
;
67
:
89
–91
110
Launbjerg
J
, Fruergaard P, Jacobsen HL, Madsen JK. Long-term risk factors from non-invasive evaluation of patients with acute chest pain, but without myocardial infarction.
Eur Heart J
 .
1995
;
16
:
30
–37
111
Nyman
I
, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
Int J Cardiol
 .
1993
;
39
:
131
–142
112
Amanullah
AM
, Lindvall K, Bevegard S. Exercise echocardiography after stabilization of unstable angina: correlation with exercise thallium-201 single photon emission computed tomography.
Clin Cardiol
 .
1992
;
15
:
585
–589
113
Amanullah
AM
, Lindvall K. Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment.
Clin Cardiol
 .
1992
;
15
:
417
–423
114
Amanullah
AM
, Lindvall K, Bevegard S. Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment.
Int J Cardiol
 .
1993
;
39
:
71
–78
115
Brown
KA
. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment [published erratum appears in J Am Coll Cardiol 1991 Sep; 18(3):889].
J Am Coll Cardiol
 .
1991
;
17
:
1053
–1057
116
Luchi
RJ
, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.
N Engl J Med
 .
1987
;
316
:
977
–984
117
Telford
AMWC
. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome.
Lancet
 .
1981
;
1
:
1225
–1228
118
Lubsen
JTJ
. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT.
Am J Cardiol
 .
1987
;
60
:
18A
–25A
119
Yusuf
S
, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
JAMA
 .
1988
;
260
:
2259
–2263
120
Eur. Heart J
 .
1985
;
6
:
199
–226
121
Kaplan
KDR
, Parker M, Przybylek J, Teagarden JR, Lesch M. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy.
Am J Cardiol
 .
1983
;
51
:
694
–698
122
DePace
N
, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action.
Arch Intern Med
 .
1982
;
142
:
1806
–1809
123
Roubin
GSHP
, Eckhardt I. Intravenous nitroglycerine in refractory unstable angina pectoris.
Aust N Z J Med
 .
1982
;
12
:
598
–602
124
Curfman
G
, Heinsimr JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective randomized trial.
Circulation
 .
1983
;
67
:
276
–282
125
Dellborg
M
, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris.
Eur J Clin Pharmacol
 .
1991
;
41
:
5
–9
126
May
DCPJ
, Podma JJ, Black WH. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries.
N Engl J Med
 .
1987
;
317
:
805
–809
127
Reichek
N
, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches.
Am J Cardiol
 .
1984
;
54
:
1
–7
128
Thadani
U
, Hamilton SF, Olsen E. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance.
Ann Intern Med
 .
1986
;
105
:
485
–492
129
Lancet
 .
2002
;
359
:
1269
–1275
130
Theroux
P
, Taeymans Y, Morissette D. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina.
J Am Coll Cardiol
 .
1985
;
5
:
717
–722
131
Parodi
O
, Simonetti I, Michelassi C. Comparison of verapamil and propanolol therapy for angina pectoris at rest. A randomized, multiple crossover, controlled trial in the coronary care unit.
Am J Cardiol
 .
1986
;
57
:
899
–906
132
Smith
NLRG
, Reiberge GE, Psaty BM. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina.
J Am Coll Cardiol
 .
1998
;
32
:
1305
–1311
133
Gibson
RS
, Young PM, Boden WE, Schechtman K, Roberts R. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study.
Am J Cardiol
 .
1987
;
60
:
203
–209
134
Gibson
RS
, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies.
Am J Cardiol
 .
2000
;
86
:
275
–279
135
Held
PYS
, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.
Br Med J
 .
1989
;
299
:
1187
–1192
136
Psaty
BM
, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies.
JAMA
 .
1995
;
274
:
620
–625
137
Yusuf
S
, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.
Am J Cardiol
 .
1991
;
67
:
1295
–1297
138
Boden
WE
, van Gilst WH, Scheldewaert RG. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT).
Lancet
 .
2000
;
355
:
1751
–1756
139
Oler
A
, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
JAMA
 .
1996
;
276
:
811
–815
140
Theroux
P
, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina.
N Engl J Med
 .
1988
;
319
:
1105
–1111
141
Lancet
 .
1996
;
347
:
561
–568
142
Eikelboom
JW
, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
Lancet
 .
2000
;
355
:
1936
–1942
143
Antman
EM
, McCabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Circulation
 .
1999
;
100
:
1593
–1601
144
Antman
EM
, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable Angina/Non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta- analysis.
Circulation
 .
1999
;
100
:
1602
–1608
145
Antman
EM
, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
Eur Heart J
 .
2002
;
23
:
308
–314
146
Ferguson
JJ
. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
J Invas Cardiol
 .
2000
;
12
:
E10
–13
147
N Engl J Med
 .
1996
;
335
:
775
–782
148
Fox
KA
. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Am J Cardiol
 .
1999
;
84
:
26M
–31M
149
Theroux
P
, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.
Circulation
 .
1993
;
88
:
2045
–2048
150
Cairns
JA
, Singer J, Gent M. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people.
Can J Cardiol
 .
1989
;
5
:
239
–246
151
BMJ
 .
2002
;
324
:
71
–86
152
Balsano
F
, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.
Circulation
 .
1990
;
82
:
17
–26
153
Yusuf
S
, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med
 .
2001
;
345
:
494
–502
154
Lancet
 .
1996
;
348
:
1329
–1339
155
Bertrand
ME
, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).
Circulation
 .
2000
;
102
:
624
–629
156
Leebeek
FWG
, Boersma E, Cannon CP, van de Werf FJJ, Simoons ML. Oral glycoprotein IIb/IIIareceptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.
Eur Heart J
 .
2002
;
23
:
444
–457
157
N Engl J Med
 .
1994
;
330
:
956
–961
158
N Engl J Med
 .
1997
;
336
:
1689
–1696
159
Lancet
 .
1998
;
352
:
87
–92
160
Circulation
 .
1997
;
96
:
1445
–1453
161
Lancet
 .
1997
;
349
:
1422
–1428
162
Lancet
 .
2000
;
356
:
2037
–2044
163
Topol
EJ
, Moliterno DJ, Herrmann HC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
N Engl J Med
 .
2001
;
344
:
1888
–1894
164
Lancet
 .
1997
;
349
:
1429
–1435
165
N Engl J Med
 .
1998
;
338
:
1498
–1505
166
N Engl J Med
 .
1998
;
338
:
1488
–1497
167
N Engl J Med
 .
1998
;
339
:
436
–443
168
Circulation
 .
1998
;
97
:
2386
–2395
169
Lancet
 .
2001
;
357
:
1915
–1924
170
Circulation
 .
2002
;
105
:
316
–321
171
Boersma
E
, Harrington R, Moliterno D. Platelet glycoproteinIIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials.
Lancet
 .
2002
;
359
:
189
–198
172
Roffi
M
, Chew DP, Mukherjee D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
Circulation
 .
2001
;
104
:
2767
–2771
173
Steinhubl
SR
, Talley JD, Braden GA. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Circulation
 .
2001
;
103
:
2572
–2578
174
Madan
M
, Tcheng JE. Update on abciximab readministration during percutaneous coronary interventions.
Curr Interv Cardiol Rep
 .
2000
;
2
:
244
–249
175
Madan
M
, Kereiakes DJ, Hermiller JB. Efficacy of abciximab readministration in coronary intervention.
Am J Cardiol
 .
2000
;
85
:
435
–440
176
Cohen
M
. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
J Invas Cardiol
 .
2000
;
12
:
E5
–9
177
James
S
, Armstrong P, Califf R. Safety and efficiency of abciximab combined with dalteparin in treatment of acute coronary syndromes.
Eur Heart J
 .
2002
;
23
:
1538
–1545
178
Circulation
 .
1993
;
87
:
38
–52
179
Karlsson
JE
, Berglund U, Bjorkholm A, Ohlsson J, Swahn E, Wallentin L. Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group.
Am Heart J
 .
1992
;
124
:
1419
–1426
180
Schreiber
TL
, Macina G, McNulty A. Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Am J Cardiol
 .
1989
;
64
:
840
–844
181
Schreiber
TL
, Macina G, Bunnell P. Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms.
Am Heart J
 .
1990
;
120
:
248
–255
182
Schreiber
TL
, Rizik D, White C. Randomized trial of thrombolysis versus heparin in unstable angina.
Circulation
 .
1992
;
86
:
1407
–1414
183
Lancet
 .
1994
;
343
:
311
–322
184
Lancet
 .
1999
;
354
:
708
–715
185
Van Belle
E
, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis.
Circulation
 .
1998
;
97
:
26
–33
186
Serruys
PW
, van Hout B, Bonnier H. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II).
Lancet
 .
1998
;
352
:
673
–681
187
Lincoff
AM
, Califf RM, Anderson KM. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications.
J Am Coll Cardiol
 .
1997
;
30
:
149
–156
188
Lincoff
AM
. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
Am J Cardiol
 .
1998
;
82
:
36P
–42P
189
Lancet
 .
1998
;
352
:
87
–92
190
Mehta
SR
, Yusuf S, Peters RJ. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Lancet
 .
2001
;
358
:
527
–533
191
Bjessmo
S
, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class.
Am Heart J
 .
2001
;
141
:
9
–14
192
Dyke
CM
, Bhatia D, Lorenz TJ. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
Ann Thorac Surg
 .
2000
;
70
:
866
–871
193
Bizzarri
F
, Scolletta S, Tucci E. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
J Thorac Cardiovasc Surg
 .
2001
;
122
:
1181
–1185
194
Clark
SC
, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery.
Ann Thorac Surg
 .
2000
;
69
:
762
–764
195
Yusuf
S
, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2.
Online J Curr Clin Trials
 .
1994
;:
196
Yusuf
S
, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2.
Online J Curr Clin Trials
 .
1994
;:
197
JAMA
 .
1997
;
277
:
715
–721
198
CABRI Investigators, First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation.Circulation, 1996, 93, 847
199
Lancet
 .
1993
;
341
:
573
–580
200
King
SB
3rd
, Lembo NJ, Weintraub WS. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST).
N Engl J Med
 .
1994
;
331
:
1044
–1050
201
Hamm
CW
, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI).
N Engl J Med
 .
1994
;
331
:
1037
–1043
202
Rodriguez
A
, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group.
J Am Coll Cardiol
 .
1993
;
22
:
1060
–1067
203
Serruys
PW
, Unger F, Sousa JE. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.
N Engl J Med
 .
2001
;
344
:
1117
–1124
204
Lagerqvist
B
, Safstrom K, Stahle E, Wallentin L, Swahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.
J Am Coll Cardiol
 .
2001
;
38
:
41
–48
205
Eur Heart J
 .
1993
;
14
:
969
–988
206
Kontny
F
. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment.
Am J Cardiol
 .
1997
;
80
:
55E
–60E
207
Lancet
 .
1990
;
336
:
827
–830
208
BMJ
 .
2002
;
324
:
71
–86
209
Schwartz
GG
, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA
 .
2001
;
285
:
1711
–1718
210
Stenestrand
U
, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival.
JAMA
 .
2001
;
285
:
430
–436
211
Stenestrand, U, Wallentin, L, Early revascularization and 1-year survival in 14-days survivors of acute myocardial infarction: a prospective cohort study. Lancet, 2002, 359, 1805, 11
212
N Engl J Med
 .
1991
;
325
:
293
–302
213
N Engl J Med
 .
1992
;
327
:
685
–691
214
Collins
R
, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
Lancet
 .
1990
;
335
:
827
–838
215
Rabbani
RTE
. Strategies to achieve coronary arterial plaque stabilization.
Cardiovasc Res
 .
1999
;
41
:
402
–417
216
Yusuf
S
, Kostis JB, Pitt B. ACE inhibitors for myocardial infarction and unstable angina.
Lancet
 .
1993
;
341
:
829
217
Yusuf
S
, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med
 .
2000
;
342
:
145
–153
218
Dagenais
GR
, Yusuf S, Bourassa MG. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
Circulation
 .
2001
;
104
:
522
–526
This content is only available as a PDF.

Comments

0 Comments